Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression

Molecular Endocrinology

Volumn 13, Issue 12, 1999, Pages 2108-2121

  Szapary, Daniele ^a   Huang, Ying ^a   Simons Jr , S Stoney ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPLIFIED IN BREAST CANCER 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; SILENCING MEDIATOR FOR RETINOID AND THYROID HORMONE RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TRANSCIPTIONAL INTERMEDIARY FACTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENHANCER REGION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 0033347396     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.12.0384     Document Type: Article

References (90)

1. Nuclear receptor coactivators and corepressors
2. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
3. The transcriptional coactivator p/CIP binds CBP and mediates nuclear-receptor function
4. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways
5. Genetic approaches to steroid hormone action
6. Specific cytoplasmic glucocorticoid hormone receptors in hepatoma tissue culture cells
7. Structure-activity relationships for glucocorticoids. Determination of receptor binding and biological activity
8. Glucocorticoid-receptor complexes in rat thymus cells. Rapid kinetic behavior and a cyclic model
9. Antiglucocorticoid steroids have increased agonist activity in those hepatoma cell lines that are more sensitive to glucocorticoids
10. Unlinked regulation of the sensitivity of primary glucocorticoid-inducible responses in mouse mammary tumor virus infected Fu5-5 rat hepatoma cells
11. The human estrogen receptor has two independent nonacidic transcriptional activation functions
12. Higher levels of control: Modulation of steroid hormone-regulated gene transcription
13. Modulation of glucocorticoid induction of tyrosine aminotransferase gene expression by variations in cell density
14. Modulation of transcription factor activity by a distant steroid modulatory element
15. Sequence-selective interactions of transcription factor elements with tandem glucocorticoid-responsive elements at physiological steroid concentrations
16. A negative tyrosine aminotransferase gene element that blocks glucocorticoid modulatory element-regulated modulation of glucocorticoid-induced gene expression
17. Modulation of tat gene induction by glucocorticoids involves a neutralizing sequence
18. Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration
19. Role of the two activating domains of the oestrogen receptor in the cell type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
20. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor
21. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
22. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell and promoter-specific action of these hormones
23. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: Functional difference between estrogen receptors α and β
24. Synergistic enhancement of PRb-mediated RU486 and R5020 agonist activities through cyclic adenosine 3', 5'-monophosphate represents a delayed primary response
25. The tau4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing
26. A complex containing N-CoR, msin3 and histone deacetylase mediates transcriptional repression
27. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
28. Transcription factor-specific requirements for coactivators and their acetyltransferase functions
29. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor
30. Dopaminergic and ligand-independent activation of steroid hormone receptors
31. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-1
32. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways
33. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP
34. Newly expressed progesterone receptor cannot activate stable, replicated mouse mammary tumor virus templates but acquires transactivation potential upon continous expression
35. Interplay of steroid hormone receptors and transcription factors on the mouse mammary tumor virus promoter
36. T1F2, a 160 kDa transcriptional mediatior for the ligand-dependent activation function AF-2 of nuclear receptors
37. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities
38. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
39. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
40. Expression and hormonal regulation of coactivator and corepressor genes
41. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
42. Nuclear protein CBP is a coactivator for the transcription factor CREB
43. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
44. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1
45. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription
46. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300
47. Creation of 'super' giucocorticoid receptors by point mutations in the steroid binding domain
48. A transcriptional co-repressor that interacts with nuclear hormone receptors
49. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
50. Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors
51. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
52. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
53. Differential effects of nuclear receptor corepressor (N-CoR) expression levels on retinoic acid receptor-mediated repression support the existence of dynamically regulated corepressor complexes
54. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
55. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor
56. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator
57. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators
58. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors
59. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2)
60. Three amino acid substitutions selectively disrupt the activation but not the repression function of the glucocorticoid receptor N terminus
61. Sinful repression
62. Chromatin remodeling and the control of gene expression
63. Transcriptional activators direct histone acetyltransferase complexes to nucleosomes
64. The transcriptional coactivators p300 and CBP are histone acetyltransferases
65. Steroid receptor coactivator-1 is a histone acetyltransferase
66. Steroid-selective initiation of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter is controlled by the site of promoter integration
67. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex
68. Determinants of chromatin disruption and transcriptional regulation instigated by the thyroid hormone receptor: Hormone-regulated chromatin disruption is not sufficient for transcriptional activation
69. Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase
70. Sequence-specific positioning of nucleosomes over the steroid-inducible MMTV promoter
71. Transcription factor loading on the MMTV promoter: A bimodal mechanism for promoter activation
72. Nucleosome-mediated disruption of transcription factor-chromatin initiation complexes at the mouse mammary tumor virus long terminal repeat in vivo
73. Activation and repression by nuclear hormone receptors: Hormone modulates an equilibrium between active and repressive states
74. Quantity of partial agonist activity for antiglucocorticoids complexed with mutant glucocorticoid receptors is constant in two different transactivation assays but not predictable from steroid structure
75. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity
76. Different classes of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain
77. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
78. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells
79. Transcriptional coregulators in development
80. Steroid binding activity is retained in a 16-kDa fragment of the steroid binding domain of rat glucocorticoid receptors
81. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation
82. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
83. Steroid-induced conformational changes at ends of the hormone binding domain in the rat glucocorticoid receptor are independent of agonist vs. antagonist activity
84. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology
85. Segregation of steroid receptor coactivator-1 from steroid receptors in mammary epithelium
86. Steroid-induced conformational changes of rat glucocorticoid receptor cause altered trypsin cleavage of the putative helix 6 in the ligand binding domain
87. Cell-specific inhibition of retinoic acid receptor-a silencing by the AF2/tc activation domain can be overcome by the corepressor SMRT, but not by NCoR
88. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations
89. How eukaryotic transcriptional activators work
90. Differential activity of progesterone and glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure